EUVIMEDEUVIMED entdecken
Crossref

Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties

Max Lewandowski iD, Melania Carmina, Loris Knümann, Minh Sai iD, Sabine Willems iD, Till Kasch, Julius Pollinger, Stefan Knapp iD, Julian A Marschner, Apirat Chaikuad iD, Daniel Merk iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.3c02095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Max Lewandowski und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Ludwig-Maximilians-Universität (LMU) München, 81377 Munich, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, Structural Genomics Consortium.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Retinoid X receptors (RXRs, NR2B1-3) hold therapeutic potential in oncology, neurodegeneration, and metabolic diseases, but traditional RXR agonists mimicking the natural ligand 9-cis retinoic acid exhibit poor physicochemical properties, pharmacokinetics, and safety profiles. Improved RXR ligands are needed to exploit RXR modulation as a promising therapeutic concept in various indications beyond its current role in second-line cancer treatment. Here, we report the co-crystal structure of RXR in complex with a novel pyrimidine-based ligand and the structure-informed optimization of this scaffold to highly potent and highly soluble RXR agonists. Focused structure-activity relationship elucidation and rigidization resulted in a substantially optimized partial RXR agonist with low nanomolar potency, no cytotoxic activity, and very favorable physicochemical properties highlighting this promising scaffold for the development of next-generation RXR targeting drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansGene Expression RegulationLigandsRetinoid X ReceptorsRetinoid X Receptor betaRetinoid X Receptor gammaRetinoid X Receptor alpha

Substanzen

Antineoplastic AgentsLigandsRetinoid X ReceptorsRXRB protein, humanRetinoid X Receptor betaRXRG protein, humanRetinoid X Receptor gammaRXRA protein, humanRetinoid X Receptor alpha

Autor:innen und Institutionen

  • Department of Pharmacy, Ludwig-Maximilians-Universität (LMU) München, 81377 Munich, Germany.
  • Department of Pharmaceutical Sciences, Università degli Studi di Perugia, 06123 Perugia, Italy.
  • Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, 60438 Frankfurt, Germany.

ORCID-Profile: Max Lewandowski, Minh Sai, Sabine Willems, Stefan Knapp, Apirat Chaikuad, Daniel Merk

Förderung

  • Deutsche Forschungsgemeinschaft
  • Structural Genomics Consortium

Zitieren

APA

Lewandowski, M., Carmina, M., Knümann, L., Sai, M., Willems, S., Kasch, T., Pollinger, J., Knapp, S., Marschner, J. A., Chaikuad, A., & Merk, D. (2024). Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c02095

Vancouver

Lewandowski M, Carmina M, Knümann L, Sai M, Willems S, Kasch T, et al. Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.3c02095

BibTeX
@article{Lewandowski2024,
  author = {Lewandowski, Max and Carmina, Melania and Knümann, Loris and Sai, Minh and Willems, Sabine and Kasch, Till and Pollinger, Julius and Knapp, Stefan and Marschner, Julian A and Chaikuad, Apirat and Merk, Daniel},
  title = {Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.3c02095}
}
Kostenlos starten →